Primary sclerosing cholangitis with IgG4-positive plasma cells in bile duct biopsies—Frequency and characterization

Abstract

Objectives: Patients diagnosed with primary sclerosing cholangitis (PSC) but with characteristics of immunoglobulin G4 (IgG4)-associated cholangitis (IAC) have been described. IAC often presents with biliary IgG4-positive plasma cell (IgG4+ PC) infiltration and responds to corticosteroids. In PSC, the frequencies or implications of biliary IgG4+ PC are unknown. We aimed to characterize the phenomenon of biliary IgG4+ PC in patients with an established PSC diagnosis.

Methods: Bile duct biopsies from 191 surveillance or therapeutic endoscopic retrograde cholangiography of 58 PSC patients were retrospectively analyzed for IgG4+ PC infiltration. Patients with ≥10 IgG4+ PC per high-power field (HPF) were identified and characterized by clinical parameters, including serum IgG4 and cholangiographic presentations.

Results: Altogether 39.7% of the PSC patients showed ≥10 IgG4+ PC/HPF in bile duct biopsies. Patients with biliary IgG4+ PC infiltration were significantly younger at diagnosis of PSC (P = 0.023). There was no association between biliary IgG4+ PC infiltration and transplant-free survival (P = 0.618). Patients with IgG4+ PC infiltration in bile duct biopsies showed significantly higher baseline (P = 0.002) and maximum (P = 0.001) serum IgG4 compared to those without. Biliary IgG4+ PC infiltration was associated with high-grade bile duct strictures (P = 0.05). IgG4-positive plasma cell infiltrations were found multifocally in 72.7% of this subgroup of PSC patients.

Conclusions: IgG4+ PC ≥10/HPF can be found abundantly in bile duct biopsies in PSC. Histological findings correlated with serum IgG4, age, and high-grade bile duct strictures. IgG4+ PC was located multifocally, hinting at a systemic biliary phenotype.

Keywords

bile ducts / biopsy / immunoglobulin G / immunoglobulin G4-related disease / primary sclerosing cholangitis

References

[1] Trivedi PJ,Bowlus CL,Yimam KK,Razavi H,Estes C. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies. Clin Gastroenterol Hepatol. 2022; 20(8):1687-1700.e4.

[2] Karlsen TH,Folseraas T,Thorburn D,Vesterhus M. Primary sclerosing cholangitis – a comprehensive review. J Hepatol. 2017; 67(6):1298-1323.

[3] Weismüller TJ,Trivedi PJ,Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017; 152(8):1975-1984.e8.

[4] Hubers LM,Maillette de Buy Wenniger LJ,Doorenspleet ME, et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol. 2015; 48(2–3):198-206.

[5] Kamisawa T,Nakazawa T,Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019; 26(1):9-42.

[6] Boonstra K,Culver EL,de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014; 59(5):1954-1963.

[7] Hirano K,Tada M,Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007; 56(12):1719-1724.

[8] Hart PA,Topazian MD,Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013; 62(11):1607-1615.

[9] Topazian M,Witzig TE,Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008; 6(3):364-366.

[10] Löhr J-M,Beuers U,Vujasinovic M, et al. European guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. United European Gastroenterol J. 2020; 8(6):637-666.

[11] Tanaka A,Tazuma S,Okazaki K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017; 15(6):920-926.e3.

[12] van Hoogstraten HJ,Vleggaar FP,Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol. 2000; 95(8):2015-2022.

[13] Angulo P,Batts KP,Jorgensen RA,LaRusso NA,Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000; 95(9):2333-2337.

[14] Strassburg CP,Beckebaum S,Geier A, et al. Practice guideline autoimmune liver diseases -AWMF-reg. No. 021-27. Z Gastroenterol. 2017; 55(11):1135-1226. [in German].

[15] Mendes FD,Jorgensen R,Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006; 101(9):2070-2075.

[16] Benito de Valle M,Müller T,Björnsson E, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis. 2014; 46(10):903-908.

[17] Björnsson E,Chari S,Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011; 18(3):198-205.

[18] Manganis CD,Chapman RW,Culver EL. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020; 26(23):3126-3144.

[19] Zhang L,Lewis JT,Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010; 34(1):88-94.

[20] Fischer S,Trivedi PJ,Ward S,Greig PD,Therapondos G,Hirschfield GM. Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol. 2014; 95(3):209-215.

[21] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022; 77(3):761-806.

[22] Pörner D,Kaczmarek DJ,Heling D, et al. Transpapillary tissue sampling of biliary strictures: balloon dilatation prior to forceps biopsy improves sensitivity and accuracy. Sci Rep. 2020; 10(1):17423.

[23] Bowlus CL,Arrivé L,Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023; 77(2):659-702.

[24] Ponsioen CY,Reitsma JB,Boberg KM,Aabakken L,Rauws EA,Schrumpf E. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy. 2010; 42(9):742-747.

[25] Zen Y,Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol. 2010; 34(12):1812-1819.

[26] Huggett MT,Culver EL,Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014; 109(10):1675-1683.

[27] Zhou T,Lenzen H,Dold L, et al. Primary sclerosing cholangitis with moderately elevated serum-IgG4 – characterization and outcome of a distinct variant phenotype. Liver Int. 2021; 41(12):2924-2933.

[28] Ricciuto A,Kamath BM,Hirschfield GM,Trivedi PJ. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem? J Hepatol. 2023; 79(2):567-575.

[29] Floreani A,Rizzotto ER,Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005; 100(7):1516-1522.

[30] Rupp C,Rössler A,Zhou T, et al. Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis. United European Gastroenterol J. 2018; 6(2):255-262.

[31] Rupp C,Hippchen T,Gotthardt D,Stiehl A,Sauer P. Scheduled endoscopic dilatation of dominant strictures improves survival in patients with primary sclerosing cholangitis. J Hepatol. 2018; 68(Suppl 1): S106.

[32] Liu X,Wang H,Liu X,Bridle K,Crawford D,Liang X. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: a systematic review and meta-analysis. Pharmacol Ther. 2022; 237:108163.

RIGHTS & PERMISSIONS

2024 The Author(s). Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.